Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. North America is one of the most prominent markets for conjugate vaccines. The conjugate vaccine market in North America is expected to expand at a CAGR of 3.2%, leading to a revenue of USD 16.26 Bn by 2023. By volume, it is anticipated to reach 286.63 Million units by 2023 expanding at a CAGR of 3%.